logo
Lung Cancer Myths, Risks And Signs, Doctor Shares Key Facts You Must Know

Lung Cancer Myths, Risks And Signs, Doctor Shares Key Facts You Must Know

News184 days ago
Last Updated:
Lung cancer is an escalating health crisis in India, caused not just by smoking but also by air pollution, genetic predisposition, and occupational hazards.
Each year on August 1, the world observes Lung Cancer Day to raise awareness about the disease and defeat the stigma associated with it. According to GLOBOCAN 2020 data by the International Agency for Research on Cancer (IARC), lung cancer remained the leading cause of cancer-related deaths in 2020, accounting for an estimated 1.8 million deaths, about 18% of all cancer fatalities, as reported by the World Health Organisation (WHO).
In India too, Lung cancer is a serious public health issue, taking thousands of lives each year and affecting both smokers and non-smokers alike. According to the Indian Journal of Medical Research (2025), the number of cases in India is expected to rise from 63,807 in 2015 to 81,219 cases in 2025
It's Not Just A Smoker's Disease
While smoking is the most widely known cause of lung cancer, in India, a growing number of non-smokers are being diagnosed due to environmental triggers.
Dr. Mohit Sharma, Clinical Director & HOD- Medical Oncology, Marengo Asia Hospitals Faridabad, highlights that the most common misconception about lung cancer is that only smokers develop lung cancer.
'While smoking is a major risk factor for lung cancer, many times, non-smokers develop lung cancer because of environmental factors, secondhand smoke exposure, genetic mutations, radon exposure, etc," Dr Sharma says.
He also notes that due to this myth, timely diagnosis in non-smokers is often put off, because early symptoms are dismissed as minor respiratory issues.
'Many people still consider lung cancer solely a smoker's disease, which is dangerous in that it fosters a false sense of security in non-smokers. Because of this misconception, many people without smoking experiences will often delay getting a checkup or diagnosis, allowing the disease to progress without medical treatment," Dr Sharma adds.
As per the National Cancer Registry and GLOBOCAN 2020, India reported 85,221 new lung cancer cases and 70,264 deaths in 2020, with an age-standardised incidence rate of 7.3 per 100,000.
Smoking is still the major contributor, responsible for around 60–70% of male cases and a significant portion among females. However, among Indian women, lung cancer doesn't feature among the top five cancers, indicating that other risk factors are at play.
Air pollution, secondhand smoke, and workplace exposure to carcinogens are increasingly affecting non-smokers.
Link Between Air Pollution and Lung Cancer in India
Air pollution, especially fine particulate matter known as PM 2.5, is a key risk factor for lung cancer in India, particularly among non-smokers.
The International Agency for Research on Cancer (IARC) categorised outdoor air pollution and PM2.5 as Group 1 carcinogens in 2013, directly linking them to lung cancer.
PM2.5 particles are tiny (less than 2.5 microns), allowing them to reach deep into the lungs, where they cause inflammation and DNA damage that can result in cancer.
Urban centres like Delhi-NCR frequently suffer from 'severe" air quality, with AQI levels above 350 due to vehicle exhaust, industrial emissions, and biomass burning.
A 2023 study in Scientific Reports showed a strong link between worsening air quality and rising lung cancer deaths in India. Predictive models were able to estimate pollution levels with 81–98% accuracy.
The Global Burden of Disease 2019 report found that 15% of global lung cancer deaths can be attributed to PM2.5 exposure, with India being one of the worst-affected regions.
In parts of Asia, including the Western Pacific, the connection between air pollution and lung cancer is especially strong. Research from the Francis Crick Institute revealed that EGFR-mutant lung cancer is more common in areas with high PM2.5 levels, putting non-smokers with genetic vulnerabilities at even greater risk.
Symptoms
Lung cancer often shows no signs until it reaches an advanced stage, making early detection difficult. The common symptoms include:
These symptoms usually develop slowly and are frequently confused with tuberculosis (TB) or other chronic lung diseases. As a result, diagnosis is often delayed.
The Tamil Nadu Cancer Registry reports that 70% of patients in India are diagnosed at an advanced stage (35% locally advanced and 35% with metastasis), which greatly reduces the chances of survival.
How Symptoms Are Often Missed Or Misunderstood
Lung cancer symptoms are commonly confused with other respiratory issues. In India, air pollution worsens asthma and chronic obstructive pulmonary disease (COPD), while TB remains a prevalent diagnosis.
Dr Sharma says, 'The diagnosis of lung cancer is often delayed because patients with symptoms of lung cancer, such as persistent or worsening cough, persistent fatigue, or unexplained shortness of breath, often attribute their symptoms to trivial conditions such as asthma or allergies."
'Perhaps, the most concerning phenomenon is that many patients seeking help from a medical professional only do so after the symptoms worsen – thus leading to late-stage diagnosis of lung cancer when treatment becomes more challenging," he adds.
Many people seek medical help only after more serious signs, such as coughing up blood or major weight loss, appear—by which time the disease may be advanced.
How Early Detection Saves Lives
Dr Sharma highlights that an early-stage lung cancer is most treatable, and screening is an important factor in detecting the disease at an early stage. Detecting lung cancer early greatly improves survival rates.
Globally, the five-year survival rate for lung cancer is between 10–20%, but early detection can significantly improve outcomes. In India, lung cancer is the fourth most common cancer, and with a high mortality rate (5.3 per 100,000), early diagnosis is especially crucial.
'Screening is highly recommended for people aged 50 and older with a history of heavy smoking or long-term exposure to certain exposures, such as pollutants (e.g., asbestos) or a family history of lung cancer," Dr Sharma says.
Dr Sharma advises individuals at higher risk to take an annual screening for lung cancer via low-dose CT scans, which have been shown to have the potential for earlier stage detection and subsequent treatment.
Low-dose computed tomography (LDCT) scans are highly effective in spotting lung cancer in people who show no symptoms but are considered high-risk, especially those aged 55–80 with a 20 pack-year smoking history or who quit recently.
What Lifestyle Changes Can Lower A Person's Risk Of Lung Cancer?
Dr Sharma explains that a few healthy lifestyle choices can reduce the chances of developing lung cancer. 'Stopping smoking and stopping environmental tobacco smoke like secondhand smoke are the most critical," he adds.
He adds that staying active, eating plenty of fruits and vegetables, and limiting alcohol intake can help lower the risk. Avoiding exposure to air pollution, radon, and workplace carcinogens also plays a key role in reducing risk and supporting overall lung health.
Quit Smoking and Avoid Tobacco: Quitting smoking is the single most effective way to reduce lung cancer risk. According to the ICMR, quitting before age 50 can reduce risk by half within 10–15 years. Avoiding smokeless tobacco (like chewing tobacco or pan) and hookah is equally important, as both beedis and cigarettes pose high risks.
Limit Secondhand Smoke Exposure: Encourage those around you to quit smoking, and steer clear of smoky areas. Secondhand smoke increases a non-smoker's lung cancer risk by up to 20%.
Reduce Exposure to Air Pollution: Avoid going outdoors when AQI levels are dangerously high (e.g., above 300), especially in polluted cities like Delhi. Wear N95 masks, use indoor air purifiers, and maintain good ventilation at home.
Exercise Regularly: Staying active strengthens lung function and boosts overall health. Even indoor workouts during high pollution periods can lower cancer risk by improving immunity, as per Hindustan Times.
Avoid Harmful Workplace Exposures: Workers in construction, mining, or industrial jobs should use proper safety gear to protect themselves from asbestos, coal dust, and other carcinogens.
Get Regular Health Check-Ups: Routine screenings for high-risk individuals—such as those with a family history or living in highly polluted areas—are vital for early detection. The Times of India stresses that knowing symptoms and accessing LDCT scans can be life-saving when facilities are available.
Progress In Lung Cancer Treatment
top videos
View all
Dr Sharma notes that lung cancer treatment has advanced significantly in recent years. Newer options like immunotherapy and targeted therapies offer more personalised, effective care with fewer side effects compared to traditional chemotherapy.
'Liquid biopsies have facilitated more timely genetic mutation detection and, as a result, therapy selection. All of the above have contributed to higher survival rates and quality of life for many individuals," he adds.
About the Author
Surbhi Pathak
Surbhi Pathak, subeditor, writes on India, world affairs, science, and education. She is currently dabbling with lifestyle content. Follow her on X: @S_Pathak_11.
Get Latest Updates on Movies, Breaking News On India, World, Live Cricket Scores, And Stock Market Updates. Also Download the News18 App to stay updated!
view comments
Location :
New Delhi, India, India
First Published:
August 01, 2025, 08:00 IST
News explainers Lung Cancer Myths, Risks And Signs, Doctor Shares Key Facts You Must Know
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26
Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26

Business Standard

timean hour ago

  • Business Standard

Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26

Ahmedabad-based Eris Lifesciences is looking to target opportunities in the nearly ₹5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced a withdrawal of its insulin products in April this year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to ₹125 crore. Revenue rose to ₹773 crore during the June quarter against ₹720 crore in the year-ago period. 'We expect that Novo's cartridge inventory in the market will run out by October. So this market opportunity is something that one can start monetising from the November-December time frame,' the company's executive director and chief executive officer (CEO) Krishnakumar Vaidyanathan told Business Standard. He added that the timing fits Eris' plans as its Bhopal unit's cartridge filling capability will start getting operational from January. Vial manufacturing has already been commissioned at the Bhopal unit, with the company creating a strategic stock of insulins. This comes at a time when Eris already is the largest domestic player in insulin. The company had last year acquired the India formulations business of Biocon Biologics last year, including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined ₹60 crore in revenue last year. Basalog and Insugen had combined revenues of ₹200 crore at the time of acquisition,' he said. He added that with this, the company's insulin franchise has become really large with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide 1) receptor agonist that is used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of the financial year 2025-26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to market is concerned, the company said it is already in a strong position because of its dominant position in insulins and prior presence in the GLP market with the launch of Liraglutide in September last year.

Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO

Economic Times

time2 hours ago

  • Economic Times

Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO

Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'

Idli vs Moong Chilla: Which Breakfast Actually Helps With Weight Loss
Idli vs Moong Chilla: Which Breakfast Actually Helps With Weight Loss

NDTV

time2 hours ago

  • NDTV

Idli vs Moong Chilla: Which Breakfast Actually Helps With Weight Loss

When you are trying to lose weight, even everyday decisions like what to eat for breakfast can feel unnecessarily complicated. You want something that is filling but not calorie-heavy. Something that tastes good but is also healthy. And most importantly, a breakfast that does not leave you hungry an hour later. The good news is that Indian breakfasts come with plenty of comforting options, but some dishes work better than others when weight loss is your priority. Two popular contenders in this space are idlis and moong chillas. Both sound healthy, but which one actually supports your weight goals better? If you often find yourself torn between the two, here is what you should know before your next breakfast. Also Read: 11 Desi Recipes To Try For Weight Loss Diet - For Breakfast, Lunch And Dinner Nutrition Comparison: Idli vs Moong Chilla One plain idli contains around 35 to 40 calories. It is low in fat and easy to digest, but primarily consists of carbohydrates since it is made using rice and urad dal. In contrast, a single moong chilla has around 120 to 130 calories. While that may sound like more, it also offers protein and dietary fibre, which help you stay full for longer. For those focusing on weight loss, moong chilla is a better pick. The protein helps control hunger, and the fibre slows digestion, both of which play key roles in managing cravings. Idlis are not a bad choice either, but they might not be as satisfying unless paired with something substantial like sambar. Which Keeps You Full Longer? If your goal is to stay full until lunch, moong chilla has the upper hand. According to Nutritionist Rashi Chowdhary, dals and dal-based batters take longer to digest, which means fewer mid-morning hunger pangs. The high protein and fibre in moong chilla also help regulate blood sugar levels, preventing sudden spikes and crashes that often trigger snacking. Idlis, though light and easy on the stomach, have a high glycaemic index and digest more quickly. So, if you eat them alone without a side like sambar, you might be rummaging through your snack drawer sooner than expected. Gut Health: Which Is Easier On The Stomach? This is where idlis come out ahead. Thanks to the fermentation process, idlis contain beneficial bacteria that support gut health and aid digestion. Their soft, fluffy texture also makes them gentle on the stomach, particularly helpful for those recovering from acidity or sensitive digestion. They are also less likely to cause bloating. On the other hand, moong chilla can sometimes lead to discomfort if your gut is not used to lentils, especially if the dal has not been soaked properly. Nutritionist Rashi Chowdhary advises soaking dals for at least four to six hours to soften their outer layer and ease digestion. Soaking not only keeps the nutrients intact but also reduces gas and bloating. That said, if lentils are a regular part of your diet, moong chilla should not cause any trouble. Weight Loss Verdict: Idli or Moong Chilla? If your main goal is managing weight and reducing cravings, moong chilla is the stronger option. It has higher amounts of protein and fibre, which help with satiety, making it a solid choice for anyone following a calorie-controlled diet. You can also boost its nutritional profile by pairing it with curd or mint chutney. That said, idlis are not off the table either. When made with ragi or oats and eaten with sambar, they become a light and gut-friendly meal. The key is to alternate between the two based on your energy needs and what your body feels like on a given day. It ultimately depends on your fitness goals and schedule. Also Read: 10 Mistakes To Avoid When You Are On Weight Loss Diet Tips To Make Your Moong Chilla Healthier 1. Add Vegetables To The Batter Moong chillas are typically plain, but you can enrich them with vegetables like grated carrots, spinach, cabbage, or capsicum. This adds fibre and micronutrients without increasing the calorie count. 2. Cook With Minimal Fat Use a cast-iron or non-stick pan, and brush it lightly with ghee. Avoid using too much oil; a small amount is enough to cook it through. 3. Pair It With Protein-Rich Curd Adding a bowl of curd on the side can balance the meal and promote digestion, thanks to the probiotics in curd. 4. Skip The Paneer Stuffing While paneer is a good protein source, it also increases the calorie count significantly. If weight loss is your goal, avoid adding paneer to your chilla. 5. Choose Whole Green Moong Whole green moong has more fibre compared to yellow moong dal. It takes slightly longer to soak but will keep you full for longer and adds a nutty depth of flavour. Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your doctor for more information. NDTV does not claim responsibility for this information. Advertisement About Nikita Nikhil Meet Nikita, a passionate soul with an insatiable love for two things in life: Bollywood and food! When she's not indulging in binge-watching sessions, Nikita can be found behind the lens capturing moments or expressing her creativity through painting. For the latest food news, health tips and recipes, like us on Facebook or follow us on Twitter and YouTube. Tags: Idli Moong Chilla Weight Loss Breakfast Show full article

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store